Description
Teduglutide Product Specifications
| Parameter | Description |
|---|---|
| Product Name | Teduglutide for Injection (Revestive ) |
| Generic Name | Teduglutide (GLP?2 analogue) |
| CAS Number | 197922?42?2 pmc.ncbi.nlm.nih.gov+2en.wikipedia.org+2mdpi.com+2 |
| Molecular Formula | C???H???N??O??S |
| Molecular Weight | ~3752?g/mol |
| Formulation | Sterile freeze-dried peptide powder for injection |
| Strength | 5?mg per vial |
| Pack Size | 28 vials per box |
| Approval Number | SJ20240008 (NMPA, China) |
| Manufacturer | Patheon Italia S.p.A. |
| Storage Conditions | Store at ?20?°C; protect from moisture and light |
| Intended Use | For laboratory research only |
Teduglutide Mechanism of Action
Teduglutide is a recombinant analogue of GLP?2 that resists DPP?IV degradation and has an extended half-life (~2 hours). It binds GLP?2 receptors to stimulate intestinal epithelial growth, increase villus height, reduce gastric motility, and enhance nutrient absorption—making it effective in models of short bowel syndrome.
Research Applications & Pharmacology
Intestinal adaptation/SBS models: Promotes mucosal proliferation, increases villus height, crypt depth, and nutrient uptake in animal models .
Parenteral nutrition studies: Demonstrated significant reductions (20–32%) in parenteral support needs in Phase III trials .
Pediatric & adult SBS: Proven efficacy in both adult and pediatric cohorts (?1?year); global approvals include the EU and US .
Tissue growth & healing research: Stimulates blood flow, epithelial integrity, and anti-secretory function .
PK/PD & dosage studies: Stabilized dosing at 0.05?mg/kg/day in line with clinical protocols.
Safety Profile & Handling
Common adverse effects: Abdominal pain, nausea, respiratory infections, injection-site reactions, fluid retention .
Severe events: Rare occurrences of intestinal obstruction, biliary complications, or congestive heart failure in extended dosing; monitor in long-term studies.
Immunogenicity: Anti?teduglutide antibody may form, but with no clear impact on safety or efficacy.
Handling: Use gloves and aseptic techniques; reconstitute with sterile solvent as instructed.
Storage & stability: Lyophilized product stored at ?20?°C; stable for up to 36 months.
Core Keywords
Teduglutide, Revestive, CAS 197922?42?2, GLP?2 analogue, short bowel syndrome research, mucosal growth peptide, lab-grade Teduglutide, parenteral nutrition reduction, wholesale Teduglutide
Research?Use Disclaimer
This product is intended exclusively for laboratory research use. It is not approved for clinical, therapeutic, diagnostic, or veterinary applications. Improper or unauthorized use may pose health hazards. Always adhere to institutional biosafety protocols.


Reviews
There are no reviews yet.